-
Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression
Wednesday, November 13, 2024 - 8:31am | 797Cybin Inc. (AMEX:CYBN) has launched its Phase 3 pivotal program called PARADIGM, which is aimed at testing the efficacy of its lead candidate, CYB003, for treating Major Depressive Disorder (MDD) in a move that comes after three years of development. "Just three years after filing an...
-
Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression
Tuesday, August 30, 2022 - 7:45pm | 571Cybin Inc. (NEO: CYBN) (NYSE AMERICAN: CYBN), a biopharmaceutical company focused on psychedelics for mental health, announced Tuesday that the first two participants have been dosed in its Phase 1/2a trial evaluating CYB003 for the treatment of the major depressive disorder (MDD). CYB003 is...
-
Major Depressive Disorder Could Soon Have Treatment Option Via Cybin's Psilocybin Analog
Tuesday, May 31, 2022 - 3:55pm | 332Cybin Inc. (CYBN), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics," has submitted an Investigational New Drug (or “IND”) application to the FDA. The aim is to begin the first phase (1/2a) of what would be the first human...